
NHS England has updated the Blueteq requirements for patients with highly active relapsing MS starting Merck’s cladribine (Mavenclad) tablets during …

NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …

In 2011, Merck KGaA had all but given up on its MS drug after having been knocked back by both …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

